Back to News
Market Impact: 0.2
Barclays Initiates Coverage of PROCEPT BioRobotics with Overweight Rating
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
Barclays initiated coverage of PROCEPT BioRobotics with an Overweight recommendation on October 7, 2026. The stock closed at $17.51 on October 6; the article text is truncated after beginning to describe recent price performance, so no further details or market reaction are available.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
PRCT0.45
More News
- Susquehanna raises Marvell stock price target on data center growth
- Cantor Fitzgerald lowers Arthur J. Gallagher price target on EPS cuts
- W P Carey stock hits 52-week low at 63.08 USD
- European bank shares fall as bond yields surge, spreads widen
- Exclusive: Meet the 38-year-old founder who left Wall Street for love and created an AI insurance unicorn a decade later
- Existential threats join bubble fears as AI mood sobers at Singapore forums
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Eli Lilly Q4 2025 Earnings: Revenue Surges 43% as Mounjaro and Zepbound Dominate the GLP-1 Market
- Investment Research Software Costs: A 2026 Budget Framework